<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05052255</url>
  </required_header>
  <id_info>
    <org_study_id>RVU120-SOL-021</org_study_id>
    <nct_id>NCT05052255</nct_id>
  </id_info>
  <brief_title>RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors</brief_title>
  <official_title>An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients With Relapse / Refractory Metastatic or Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ryvu Therapeutics SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ryvu Therapeutics SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1/2, dose-escalation and expansion study investigating the safety,&#xD;
      pharmacokinetics, and efficacy of RVU120 (SEL120) in patients with metastatic or advanced&#xD;
      solid tumors progressing from previous lines of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose-escalation phase (Part 1) will be followed by an expansion phase (Part 2). Part 1&#xD;
      will evaluate the safety/tolerability and pharmacokinetics of increasing doses of RVU120&#xD;
      (SEL120) administered as a single dose every other day (7 doses in a 3 week cycle). Part 2&#xD;
      will collect additional data on safety, pharmacokinetics and efficacy at the recommended dose&#xD;
      in patients with tumor types selected in Part 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events in part I</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluation of frequency and nature of adverse events, serious adverse events and dose limiting toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose Finding in part I</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Determination of Recommended phase 2 dose assessing all available data</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Overall Response in part II</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective Overall Response as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1 (v1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response in part II</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of Response, as Assessed by RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival in part II</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression Free Survival as Assessed by RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival in part II</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessment of Overall Survival from the date of first dose until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed of the maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Plasma Concentration (Cmin)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed of the minimum plasma concentration (Cmin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed of the Time to Cmax (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed of the Area Under the Concentration Time-Curve (AUC) from Time Zero to Dosing Interval (AUC0-tau)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Overall Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Objective Overall Response as Assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Duration of Response, as Assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Progression Free Survival as Assessed by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessment of Overall Survival from the date of first dose until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Escalation / Part 2: Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1-Dose Escalation: Escalating doses of RVU120, in patients who have progressed from previous therapy.&#xD;
Part 2-Cohort Expansion: Recommended dose in patients with tumor types selected from part 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVU120</intervention_name>
    <description>RVU120 will be administered as a single oral dose every other day for a total of 7 doses over a 3 week treatment cycle until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Part 1: Dose Escalation / Part 2: Cohort Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Signed informed consent prior to initiation of any study-specific procedures and&#xD;
             treatment&#xD;
&#xD;
          -  Pathologically confirmed advanced solid tumor for which no standard therapy is&#xD;
             available&#xD;
&#xD;
          -  Progressive disease, measurable according to RECIST v1.1&#xD;
&#xD;
          -  ECOG Performance Status 0-2&#xD;
&#xD;
          -  Adequate organ function based on laboratory values&#xD;
&#xD;
          -  Complete recovery from major surgery (stable and toxicity sequelae less than or equal&#xD;
             to grade 2, as determined by NCI CTCAE v5.0&#xD;
&#xD;
          -  Able to provide an archival or fresh tumor biopsy sample at screening&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Radiotherapy within 28 days prior to initiation of study treatment (except 14 days for&#xD;
             palliative radiotherapy)&#xD;
&#xD;
          -  Anti-cancer medication or high-dose systemic corticosteroids prior to initiation of&#xD;
             study treatment&#xD;
&#xD;
          -  Active brain metastases&#xD;
&#xD;
          -  Prior history of or planned organ or hematopoietic stem cell transplant&#xD;
&#xD;
          -  Ongoing uncontrolled systemic infection, acute inflammatory condition, significant&#xD;
             liver disease, gastrointestinal disease, or clinically significant cardiovascular&#xD;
             disease&#xD;
&#xD;
          -  Presence of an acute or chronic toxicity of prior chemotherapy that has not resolved&#xD;
             to less then or equal to grade 1, as determined by CTCAE v5.0, except for alopecia,&#xD;
             lymphopenia assessed as non-clinically significant, sensory neuropathy and erectile&#xD;
             dysfunction that could be less than or equal to grade 2&#xD;
&#xD;
          -  Taking medications or supplements known to be strong inhibitors or strong inducers or&#xD;
             sensitive substrates of CYP1A2&#xD;
&#xD;
          -  Taking medication that risk prolonged QTc or TdP&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Head of Clinical Operations</last_name>
    <phone>+48 538 898 766</phone>
    <email>clinicaltrials@ryvu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University Early Phase 1 Research Center / Uniwersyteckie Centrum Kliniczne Ośrodek Badań Klinicznych Wczesnych Faz</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafał Dziadziuszko, MD</last_name>
      <phone>+48 58 584 45 71</phone>
    </contact>
    <investigator>
      <last_name>Rafał Dziadziuszko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maria Sklodowska-Curie National Research Institute of Oncology / Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy</name>
      <address>
        <city>Warsaw</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Ługowska, MD</last_name>
      <phone>+48 22 546 33 81</phone>
    </contact>
    <investigator>
      <last_name>Iwona Ługowska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapse</keyword>
  <keyword>Refractory</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Advanced</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

